Positive Outlook and Buy Rating for Autolus Therapeutics Driven by Strategic Developments and Promising Prospects

Mizuho Securities analyst Salim Syed has maintained their bullish stance on AUTL stock, giving a Buy rating yesterday.

Salim Syed’s rating is based on several strategic developments and promising prospects for Autolus Therapeutics. One of the key factors is the successful ongoing launch of Aucatzyl, a treatment for adult relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), which has already seen authorization in 33 U.S. treatment centers. This number is expected to grow, potentially covering up to 90% of the target patient population by the end of 2025. The expansion of authorized centers is anticipated to be driven by provider interest and patient demand, with the potential for increased repeat usage as familiarity with the product grows.
Additionally, Salim Syed highlights the promising pipeline developments, including the expected initial data for systemic lupus erythematosus (SLE) at an upcoming R&D event. The company’s manufacturing process for Aucatzyl is also noted to be efficient, with a turnaround time that aligns well with their pivotal study experiences. These factors, combined with the anticipation of further updates on other pipeline products, contribute to the positive outlook and the Buy rating for Autolus Therapeutics.

AUTL’s price has also changed dramatically for the past six months – from $3.730 to $1.675, which is a -55.09% drop .